<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24959738</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys.</ArticleTitle><Pagination><StartPage>e100130</StartPage><MedlinePgn>e100130</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e100130</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0100130</ELocationID><Abstract><AbstractText>Knowledge of virulence and immunogenicity is important for development of live-attenuated dengue vaccines. We previously reported that an infectious clone-derived dengue type 4 virus (DENV-4) passaged in MRC-5 cells acquired a Glu345Lys (E-E345K) substitution in the E protein domain III (E-DIII). The same cloned DENV-4 was found to yield a single E-Glu327Gly (E-E327G) mutation after passage in FRhL cells and cause the loss of immunogenicity in rhesus monkeys. Here, we used site-directed mutagenesis to generate the E-E345K and E-E327G mutants from DENV-4 and DENV-4&#x394;30 infectious clones and propagated in Vero or MRC-5 cells. The E-E345K mutations were consistently presented in viruses recovered from MRC-5 cells, but not Vero cells. Recombinant E-DIII proteins of E345K and E327G increased heparin binding correlated with the reduced infectivity by heparin treatment in cell cultures. Different from the E-E327G mutant viruses to lose the immunogencity in rhesus monkeys, the E-E345K mutant viruses were able to induce neutralizing antibodies in rhesus monkeys with an almost a 10-fold lower level of viremia as compared to the wild type virus. Monkeys immunized with the E-E345K mutant virus were completely protected with no detectable viremia after live virus challenges with the wild type DENV-4. These results suggest that the E-E345K mutant virus propagated in MRC-5 cells may have potential for the use in live-attenuated DENV vaccine development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hsiao-Han</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hsiang-Chi</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Feng</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Meng-Ju</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Hung-Ju</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Jia-Guan</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sue</LastName><ForeName>Shih-Che</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Institute of Bioinformatics and Structural Biology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Cheng-Feng</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan; Department of Medical Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C466981">glycoprotein E, dengue virus type 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="Y">Viremia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have read the journal's policy and have the following conflicts. HHL, HCL, HJH, SCW are named on Taiwan Patent I434936. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. All other authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24959738</ArticleId><ArticleId IdType="pmc">PMC4069063</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0100130</ArticleId><ArticleId IdType="pii">PONE-D-14-12549</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (2014) Dengue and severe dengue. Fact sheet N&#xb0;117. Available: http://www.who.int/mediacentre/factsheets/fs117/en/. Accessed 2014 June 3.</Citation></Reference><Reference><Citation>Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, et al. (2011) From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29: 7229&#x2013;7241.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745521</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio JE, Huang CY, Kinney RM, Stinchcomb DT (2011) Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccines for protection against dengue fever. Vaccine 29: 7251&#x2013;7260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4592106</ArticleId><ArticleId IdType="pubmed">21777638</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS (2011) Development and clinical evaluation of multiple investigational monovalent dengue vaccines to identify components for inclusion in a live attenuated tetravalent dengue vaccine. Vaccine 29: 7242&#x2013;7250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170437</ArticleId><ArticleId IdType="pubmed">21781997</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE Jr, Johnson DH, Manipon GG, Firestone CY, Hanson CT, et al. (2002) Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300: 125&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202213</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE Jr, Manipon GG, Firestone CY, Johnson DH, Hanson CT, et al. (2003) Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 21: 4317&#x2013;4327.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505914</ArticleId></ArticleIdList></Reference><Reference><Citation>Butrapet S, Kinney RM, Huang CY (2006) Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. J Virol Methods 131: 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16087248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantel N, Girerd Y, Geny C, Bernard I, Pontvianne J, et al. (2011) Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 29: 6629&#x2013;6635.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745519</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lee SC, Butler M, Wu SC (2008) High genetic stability of dengue virus propagated in MRC-5 cells as compared to the virus propagated in Vero cells. PLoS ONE 3: e1810 10.1371/journal.pone.0001810</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001810</ArticleId><ArticleId IdType="pmc">PMC2265545</ArticleId><ArticleId IdType="pubmed">18350148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HC, Yen YT, Chen WY, Wu-Hsieh BA, Wu SC (2011) Dengue type 4 live-attenuated vaccine viruses passaged in Vero cells affect genetic stability and dengue-induced hemorrhaging in mice. PLoS ONE 10: e25800 10.1371/journal.pone.0025800</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025800</ArticleId><ArticleId IdType="pmc">PMC3203870</ArticleId><ArticleId IdType="pubmed">22053180</ArticleId></ArticleIdList></Reference><Reference><Citation>A&#xf1;ez G, Men R, Eckels KH, Lai CJ (2009) Passage of dengue virus type 4 vaccine candidates in fetal Rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in Rhesus monkeys. J Virol 83: 10384&#x2013;10394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753127</ArticleId><ArticleId IdType="pubmed">19656873</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CJ, Zhao BT, Hori H, Bray M (1991) Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci U. S. A 88: 5139&#x2013;5143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51827</ArticleId><ArticleId IdType="pubmed">2052593</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk DE, Lee YC, Li X, Thiviyanathan V, Gromowski GD, et al. (2007) Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364: 147&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950219</ArticleId><ArticleId IdType="pubmed">17395234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, et al. (2004) Conformational changes of the flavivirus E glycoprotein. Structure 12: 1606&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152830</ArticleId><ArticleId IdType="pubmed">15341726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Lobigs M (2008) E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol 82: 6024&#x2013;6033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395160</ArticleId><ArticleId IdType="pubmed">18400851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, et al. (2001) Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 75: 5627&#x2013;5637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114275</ArticleId><ArticleId IdType="pubmed">11356970</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Wright PJ, Davidson A, Lobigs M (2006) Virulence attenuation of dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 87: 2791&#x2013;2801.</Citation><ArticleIdList><ArticleId IdType="pubmed">16963737</ArticleId></ArticleIdList></Reference><Reference><Citation>Watterson D, Kobe B, Young PR (2011) Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. J Gen Virol 93: 72&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21957126</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, et al. (1997) Dengue virus infectivity depends on envelope protein binding to heparan sulfate. Nat Med 3: 886&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">9256277</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, et al. (2003) A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3&#x2032; untranslated region is highly attenuated and immunogenic in monkeys. J Virol 77: 1653&#x2013;1657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140839</ArticleId><ArticleId IdType="pubmed">12502885</ArticleId></ArticleIdList></Reference><Reference><Citation>Men R, Bray M, Clark D, Chanock RM, Lai CJ (1996) Dengue type 4 virus mutants containing deletions in the 3&#x2032;noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 70: 3930&#x2013;3937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190271</ArticleId><ArticleId IdType="pubmed">8648730</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, et al. (2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3&#x2032;-untranslated region. Am. J. Trop. Med. Hyg 65: 405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">11716091</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, et al. (2005) rDEN4 delta 30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191: 710&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Bhamarapravati N, et al. (1997) Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230: 300&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143286</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, et al. (2000) Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74: 3020&#x2013;3028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111800</ArticleId><ArticleId IdType="pubmed">10708416</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalrymple N, Mackow ER (2011) Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors. J Virol 85: 9478&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3165770</ArticleId><ArticleId IdType="pubmed">21734047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervaeke P, Alen M, Noppen S, Schols D, Oreste P, et al. (2013) Sulfated Escherichia coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III. PLoS One 28: e74035 10.1371/journal.pone.0074035</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0074035</ArticleId><ArticleId IdType="pmc">PMC3755990</ArticleId><ArticleId IdType="pubmed">24015314</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F, Zhang Z, Myers G, Johnson BW, Pugachev K, et al. (2004) A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol 78: 9998&#x2013;10008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC514991</ArticleId><ArticleId IdType="pubmed">15331733</ArticleId></ArticleIdList></Reference><Reference><Citation>Keelapang P, Nitatpattana N, Suphatrakul A, Punyahathaikul S, Sriburi R, et al. (2013) Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage. Vaccine 31: 5134&#x2013;5140.</Citation><ArticleIdList><ArticleId IdType="pubmed">23973247</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;st R, Dong H, Li XF, Chang DC, Zhang B, et al. (2013) Rational design of a live attenuated dengue vaccine: 2&#x2032;-O-Methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog 9: e1003521 10.1371/journal.ppat.1003521</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003521</ArticleId><ArticleId IdType="pmc">PMC3731252</ArticleId><ArticleId IdType="pubmed">23935499</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XF, Deng YQ, Yang HQ, Zhao H, Jiang T, et al. (2013) A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol 87: 13694&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838253</ArticleId><ArticleId IdType="pubmed">24109223</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>